Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) shares rose 8.6% on Wednesday . The stock traded as high as $8.37 and last traded at $8.32. Approximately 30,048,190 shares were traded during trading, an increase of 50% from the average daily volume of 19,970,264 shares. The stock had previously closed at $7.66.
Analysts Set New Price Targets
RXRX has been the subject of several recent analyst reports. KeyCorp decreased their price objective on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a research report on Wednesday, January 8th. Needham & Company LLC reiterated a "buy" rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday, February 6th.
Get Our Latest Report on Recursion Pharmaceuticals
Recursion Pharmaceuticals Stock Performance
The firm has a market capitalization of $4.11 billion, a P/E ratio of -6.88 and a beta of 0.86. The company's 50 day moving average is $7.27 and its 200-day moving average is $6.91. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC bought a new position in Recursion Pharmaceuticals during the third quarter worth $25,000. Decker Retirement Planning Inc. bought a new position in shares of Recursion Pharmaceuticals in the fourth quarter valued at $26,000. Private Trust Co. NA bought a new position in shares of Recursion Pharmaceuticals in the fourth quarter valued at $27,000. GAMMA Investing LLC lifted its stake in shares of Recursion Pharmaceuticals by 1,979.2% in the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company's stock valued at $35,000 after buying an additional 4,948 shares in the last quarter. Finally, Farther Finance Advisors LLC lifted its stake in shares of Recursion Pharmaceuticals by 176.9% in the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company's stock valued at $42,000 after buying an additional 4,091 shares in the last quarter. 89.06% of the stock is owned by institutional investors.
About Recursion Pharmaceuticals
(
Get Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Featured Articles
Before you consider Recursion Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.
While Recursion Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
